Pulmonary complications of biological therapies in children and adults with rheumatic diseases.
Paediatr Respir Rev
; 14(4): 236-41, 2013 Dec.
Article
in En
| MEDLINE
| ID: mdl-23462434
ABSTRACT
The management of rheumatic conditions, including those occurring in children, has improved dramatically over the last decade following the introduction of biologic disease-modifying anti-rheumatic drugs (bDMARDS) into the therapeutic arsenal. The benefits have been realised in multiple aspects of disease including signs and symptoms, bone and cartilage destruction, disability and quality of life. Overall, bDMARDS have an acceptable safety profile in the short to medium term in adults and children, however, that following longer term use remains unclear. As these drugs target key signalling molecules and cells of the immune system, adverse events are not unanticipated. In this review we will discuss pulmonary complications of biologic therapies used in the management of rheumatic diseases in both children and adults.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Biological Therapy
/
Biological Factors
/
Rheumatic Diseases
/
Antirheumatic Agents
/
Immune System
/
Lung Diseases
Type of study:
Incidence_studies
/
Prognostic_studies
Aspects:
Patient_preference
Limits:
Adult
/
Child
/
Humans
Language:
En
Journal:
Paediatr Respir Rev
Journal subject:
PEDIATRIA
Year:
2013
Document type:
Article